S.R. Schill & Associates’s Gilead Sciences GILD Stock Holding History

S.R. Schill & Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,188	Closed	-$266K	–	70
2016 Q2	$266K	Buy	3,188 +178	+6%	+$15.8K	0.18%	54
2016 Q1	$276K	Buy	3,010 +312	+12%	+$28.1K	0.19%	56
2015 Q4	$273K	Sell	2,698 -11	-0.4%	-$1.15K	0.19%	58
2015 Q3	$266K	Hold	2,709	–	–	0.19%	60
2015 Q2	$317K	Buy	+2,709	New	+$296K	0.21%	58

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

S.R. Schill & Associates's GILD Position: Q3 2016 in Review

S.R. Schill & Associates sold out of Gilead Sciences (GILD) in Q3 2016, closing a stake of 3,188 shares — an estimated $266K sold.

S.R. Schill & Associates first reported a position in GILD in Q2 2015 and held it in 5 quarters. The position peaked at $317K in Q2 2015. 1,558 funds tracked by Wall St. Rank hold GILD as of Q3 2016.

S.R. Schill & Associates reported no remaining Gilead Sciences position as of Q3 2016 after selling out during the quarter.
S.R. Schill & Associates sold 3,188 Gilead Sciences shares in Q3 2016, an estimated $266K.
S.R. Schill & Associates first reported a position in Gilead Sciences in Q2 2015 and held it in 5 quarters.
S.R. Schill & Associates's Gilead Sciences position peaked at $317K in Q2 2015.
1,558 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2016.

Based on S.R. Schill & Associates's 13F filing for Q3 2016, filed 3 Nov 2016.